Clinical trials
Liver clinical trials
Below are recruiting liver clinical trials, each written for real people, not researchers. We’re tracking 1,253 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT07087054RecruitingPhase 3
A daily pill for carcinoid syndrome symptoms
This trial tests an oral daily medication, paltusotine, to reduce flushing and other symptoms of carcinoid syndrome in people with neuroendocrine tumors. It may be an option for those who need treatment and have stable disease.
Gilbert, ArizonaAges 18 years+ - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT04634643Recruiting
Studies what causes fatty liver in teens
This study looks at why “nonalcoholic fatty liver disease” happens in teenagers and how it develops. It may help doctors better predict and prevent liver problems in children, even if there isn’t a new drug for you to take.
New Haven, ConnecticutAges 12–18 - NCT07735182Recruiting
Gut bacteria and organ damage in sepsis
This study looks at how bacteria in your gut and other signs in your body affect liver and kidney damage in people with sepsis. It also compares findings to healthy volunteers to see what is different.
Hangzhou, ZhejiangAges 18 years+ - NCT03855917RecruitingPhase 4
Short 4-week hepatitis C treatment for early liver disease
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
Darlinghurst, New South WalesAges 18 years+ - NCT07409805RecruitingPhase 1
Vaccine trial for advanced colorectal cancer with liver spread
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
Chengdu, SichuanAges 18–75 - NCT06723275Recruiting
A study on liver transplant for different liver diseases
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
Ghent, BelgiumAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT07059494RecruitingPhase 4
Combination therapy for liver cancer before transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
New York, New YorkAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT06512454Recruiting
Study on inherited alpha-1 antitrypsin deficiency and related liver problems
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
Gainesville, FloridaAges 18 years+ - NCT06755632Recruiting
Hepatic fibrosis or cirrhosis screening trial
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
BobignyAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT04272515Recruiting
Learn from tissue or samples from biliary atresia patients
This study looks to better understand biliary atresia by studying patient information and/or samples. It may help researchers learn why the condition happens and how to improve care.
Paris, DeAges Any age - NCT05835505RecruitingPhase 2
Detox medicine study for primary sclerosing cholangitis
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
Chestnut Hill, MassachusettsAges 18–75 - NCT07707778Enrolling by invitationPhase 4
Tirzepatide for Weight and Aging in People with HIV
This trial tests whether a weight-loss medicine called tirzepatide can slow biological aging and improve metabolism in people with HIV who are already on effective treatment. It may help you reduce weight and possibly reverse some signs of aging.
TaipeiAges 18 years+ - NCT03151473Recruiting
Study of adults with fatty liver and NASH over time
This is a long-term study that follows adults who are being managed for fatty liver (NAFL) or NASH to learn how these conditions change over time. It may help researchers better understand what to expect and how care decisions could be improved.
Hong KongAges 18 years+ - NCT03190538Recruiting
Study of fatty liver inflammation in Chinese children
This trial looks at nonalcoholic steatohepatitis (fatty liver with inflammation) in children. It is meant to test whether a new approach can help improve this liver problem without being caused by alcohol or other known liver diseases.
BeijingAges 1–18 - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT03403686Recruiting
Study eye treatment target for diabetic retinopathy
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
Birmingham, AlabamaAges 21–98 - NCT03472157Recruiting
Bariatric surgery for severe NASH with advanced liver scarring
This study tests whether bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) improves severe nonalcoholic steatohepatitis (NASH) with advanced liver scarring in people who are obese. You may also need liver biopsies to confirm your liver disease before and after treatment.
LilleAges 18–65
Hear when a new Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver?
- Yes. Clin2 currently lists 1,253 recruiting liver studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.